ImmunoGen, Inc.
IMGNNASDAQHealthcare
$31.24
+$0.01(+0.02%)
Market Cap$8.7B
P/E Ratio—
52W High$31.25
52W Low$3.61
ImmunoGen, Inc. (IMGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMGN · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 6, 2024EPS Actual
-$0.23
Est. $0.13 · -276.9%
Revenue
—
Est. $0.13B
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 6, 2024
After Market Close
▼ Miss EPS
IMGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2024 | Oct 31, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Jul 29, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | Apr 26, 2024 | — | — | — | — | — | — |
| ▼ Q1 FY2024 | Mar 6, 2024 | $0.13 | -$0.23 | -276.9% | — | $0.13B | — |
| ▲ Q4 FY2023 | Nov 2, 2023 | $0.04 | $0.10 | +124.1% | $0.11B | $0.13B | -11.3% |
| ▲ Q3 FY2023 | Jul 31, 2023 | -$0.16 | -$0.02 | +87.5% | $0.08B | $0.05B | +72.0% |
| ▲ Q2 FY2023 | Apr 28, 2023 | -$0.25 | -$0.16 | +36.0% | $0.05B | $0.02B | +143.6% |
| ▲ Q1 FY2023 | Mar 1, 2023 | -$0.29 | -$0.23 | +20.7% | $0.04B | $0.02B | +137.8% |
Q4 FY2024
Oct 31, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Jul 29, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Apr 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 6, 2024Miss
EPS Actual
-$0.23
EPS Est.
$0.13
EPS Surpr.
-276.9%
Revenue
—
Q4 FY2023
Nov 2, 2023Beat
EPS Actual
$0.10
EPS Est.
$0.04
EPS Surpr.
+124.1%
Revenue
$0.11B
Q3 FY2023
Jul 31, 2023Beat
EPS Actual
-$0.02
EPS Est.
-$0.16
EPS Surpr.
+87.5%
Revenue
$0.08B
Q2 FY2023
Apr 28, 2023Beat
EPS Actual
-$0.16
EPS Est.
-$0.25
EPS Surpr.
+36.0%
Revenue
$0.05B
Q1 FY2023
Mar 1, 2023Beat
EPS Actual
-$0.23
EPS Est.
-$0.29
EPS Surpr.
+20.7%
Revenue
$0.04B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2025 | $-1.96 | $1.54 | $4.90 | 11 |
| Q4 FY2024 | $-1.71 | $1.34 | $4.27 | 11 |
| Q3 FY2024 | $-0.03 | $0.02 | $0.06 | 3 |
| Q2 FY2024 | $-0.17 | $0.04 | $0.17 | 3 |
| Q1 FY2024 | $-0.20 | $0.09 | $0.13 | 5 |
| Q4 FY2023 | $0.20 | $-0.16 | $-0.51 | 12 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2025 | $0.2B | $0.2B | $0.3B | 18 |
| Q4 FY2024 | $0.1B | $0.2B | $0.3B | 19 |
| Q3 FY2024 | $0.0B | $0.0B | $0.1B | 2 |
| Q2 FY2024 | $0.0B | $0.1B | $0.1B | 2 |
| Q1 FY2024 | $0.1B | $0.1B | $0.1B | 4 |
| Q4 FY2023 | $0.0B | $0.0B | $0.1B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Mar 6, 2024 | -276.9% | $31.23 | — | — |
| ▲ Q4 FY2023 | Nov 2, 2023 | +124.1% | $14.94 | $15.50 | +3.75% |
| ▲ Q3 FY2023 | Jul 31, 2023 | +87.5% | $19.52 | $17.82 | -8.71% |
| ▲ Q2 FY2023 | Apr 28, 2023 | +36.0% | $4.32 | $5.39 | +24.77% |
| ▲ Q1 FY2023 | Mar 1, 2023 | +20.7% | $3.88 | $4.02 | +3.61% |
| ▼ Q4 FY2022 | Nov 4, 2022 | -19.2% | $5.67 | $5.57 | -1.76% |
| ▼ Q3 FY2022 | Jul 29, 2022 | -9.1% | $5.25 | $4.74 | -9.71% |
| ▲ Q2 FY2022 | May 6, 2022 | +52.4% | $4.85 | $4.63 | -4.54% |
Q1 FY2024—
Report Date
Mar 6, 2024
EPS Beat/Miss
-276.9%
Price Before
$31.23
Price After
—
Q4 FY2023+3.75%
Report Date
Nov 2, 2023
EPS Beat/Miss
+124.1%
Price Before
$14.94
Price After
$15.50
Q3 FY2023-8.71%
Report Date
Jul 31, 2023
EPS Beat/Miss
+87.5%
Price Before
$19.52
Price After
$17.82
Q2 FY2023+24.77%
Report Date
Apr 28, 2023
EPS Beat/Miss
+36.0%
Price Before
$4.32
Price After
$5.39
Q1 FY2023+3.61%
Report Date
Mar 1, 2023
EPS Beat/Miss
+20.7%
Price Before
$3.88
Price After
$4.02
Q4 FY2022-1.76%
Report Date
Nov 4, 2022
EPS Beat/Miss
-19.2%
Price Before
$5.67
Price After
$5.57
Q3 FY2022-9.71%
Report Date
Jul 29, 2022
EPS Beat/Miss
-9.1%
Price Before
$5.25
Price After
$4.74
Q2 FY2022-4.54%
Report Date
May 6, 2022
EPS Beat/Miss
+52.4%
Price Before
$4.85
Price After
$4.63
Avg Beat Reaction+3.78%
Avg Miss Reaction-5.74%
Beat Rate5 / 8 quarters
Largest Move+24.77% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMGN ends December
ImmunoGen, Inc. (IMGN) most recently reported earnings on March 6, 2024 for Q1 FY2024, posting EPS of $-0.23 — missing the analyst consensus of $0.13 by -276.9%. The next IMGN earnings date is expected around September 1, 2026.
Each quarter, investors track IMGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMGN earnings · 5 questionsImmunoGen, Inc.'s next earnings report is expected around September 1, 2026. IMGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMGN historically reports after market close (AMC).
IMGN earnings datewhen is IMGN earningsIMGN next earnings datewhen does IMGN report earningsIMGN earnings calendar
▸ Source: FMP · ImmunoGen, Inc. SEC filings · US GAAP · ImmunoGen, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026